Clinical Trials Logo
  1. Home
  2. Proteinuria
  3. NCT00568178

An Extension Study Designed to Assess Effects of Losartan on Proteinuria in Pediatric Populations (MK-0954-326 AM1,EXT1(AM2))

Proteinuria Clinical Trial

Official title:
A Randomized, Double-Blind, Parallel, Placebo or Amlodipine-Controlled Study of the Effects of Losartan on Proteinuria in Pediatric Patients With or Without Hypertension

Clinical Trial Summary

The purpose of this study is to evaluate the effects of losartan on proteinuria in pediatric patients.

Clinical Trial Description

The study included a 12-week double-blind treatment phase and a 36-month open-label extension phase. Participants who completed or discontinued the initial 12-week phase of the study and who opted to participate in the open label extension phase were randomized to either losartan or enalapril at a dose of the investigator's choosing for the duration of the extension. The open label extension was designed to continue until the 100th participant completed 3 years of follow-up. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00568178
Study type Interventional
Source Organon and Co
Contact
Status Completed
Phase Phase 3
Start date June 1, 2007
Completion date March 1, 2011
View Details
See also
  Status Clinical Trial Phase
Completed NCT03510286 - Validation of a PrCr Dipstick Diagnostic Test in Ghana
Completed NCT05086549 - An Observation Study to Evaluate the Renoprotective Effect of Fimasartan in Patients With DKD and Proteinuria
Terminated NCT04051957 - Isosorbide Mononitrate For Anti-Vascular Endothelial Growth Factor (VEGF) Induced Kidney Injury Phase 2
Terminated NCT02057523 - Acthar as Rescue Therapy for Transplant Glomerulopathy in Kidney Transplant Recipients Phase 4
Completed NCT02226055 - An Investigation Into the Cardiovascular Risk and Aetiology of CKDu in Sri Lanka N/A
Completed NCT02232763 - Efficacy and Safety of Losartan in Pediatric Chronic Kidney Disease With Tubular Proteinuria Phase 3
Completed NCT00493727 - Use of Mucomyst to Ameliorate Oxidant Stress in Diabetics With Proteinuria N/A
Active, not recruiting NCT00565396 - Effectiveness Study on Fosinopril and/or Losartan in Patients With Chronic Kidney Disease Stage 3 N/A
Recruiting NCT05759754 - Effects of Traditional Chinese Medicine (GSJYF) in Children With Inherited Proteinuric Kidney Disease N/A
Withdrawn NCT02882373 - Arginine in Treating Patients With Anti-VEGF Induced Kidney Injury Phase 2
Completed NCT02327403 - Belatacept Conversion in Proteinuric Kidney Transplant Recipients Phase 2
Recruiting NCT01773382 - The Effects of Weight Reduction in IgA Nephropathy N/A
Completed NCT00915200 - N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy Phase 2
Completed NCT01029002 - The Effects of Vitamin D Repletion in Vitamin D Deficient Patients With Stage 3 and 4 Chronic Kidney Disease Phase 3
Withdrawn NCT00541619 - Sympathetic Overactivity in Essential Hypertension N/A
Withdrawn NCT00392132 - Impact of Screening Patients With HIV for Kidney Disease
Terminated NCT00001978 - Determination of Kidney Function
Recruiting NCT05457283 - A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria Phase 3
Completed NCT04874753 - The Effect of COVID-19 Pandemia on Follow up of Patients With Chronic Kidney Disease
Recruiting NCT02972346 - Availability Study of ACTH to Treat Children SRNS/SDNS N/A